

**MEDNAX, INC.**  
**RECONCILIATION OF DILUTED INCOME FROM CONTINUING OPERATIONS PER SHARE**  
**TO ADJUSTED DILUTED INCOME FROM CONTINUING OPERATIONS ATTRIBUTABLE TO MEDNAX, INC. PER DILUTED SHARE ("ADJUSTED EPS FROM CONTINUING OPERATIONS")**  
(in thousands, except per share data)  
(Unaudited)

	2021									
	Three Months Ended March 31, 2021		Three Months Ended June 30, 2021		Three Months Ended September 30, 2021		Three Months Ended December 31, 2021		Twelve Months Ended December 31, 2021	
Weighted average diluted shares outstanding	85,491		85,933		86,096		86,245		85,828	
Income from continuing operations and diluted income from continuing operations per share attributable to Mednax, Inc.	\$ 5,352	\$ 0.06	\$ 30,533	\$ 0.36	\$ 31,847	\$ 0.37	\$ 40,282	\$ 0.47	\$ 108,014	\$ 1.26
Adjustments <sup>(1)</sup> :										
Amortization (net of tax)	2,672	0.03	1,728	0.02	1,749	0.02	1,780	0.02	7,928	\$ 0.09
Stock-based compensation (net of tax)	2,788	0.03	4,301	0.04	4,121	0.05	3,015	0.03	14,226	\$ 0.16
Transformational and restructuring related expenses (net of tax)	3,659	0.04	7,449	0.09	3,174	0.03	2,294	0.03	16,575	\$ 0.19
Gain on sale of building (net of tax)	-	-	(5,460)	(0.06)	-	-	-	-	(5,460)	\$ (0.06)
Loss on early extinguishment of debt (net of tax)	10,899	0.13	-	-	-	-	-	-	10,899	\$ 0.13
Net impact from discrete tax events	(5,067)	(0.05)	(3,516)	(0.04)	(901)	(0.01)	(2,672)	(0.03)	(12,156)	\$ (0.14)
Adjusted income and diluted EPS from continuing operations attributable to Mednax, Inc.	<u>\$ 20,303</u>	<u>\$ 0.24</u>	<u>\$ 35,035</u>	<u>\$ 0.41</u>	<u>\$ 39,990</u>	<u>\$ 0.46</u>	<u>\$ 44,699</u>	<u>\$ 0.52</u>	<u>\$ 140,026</u>	<u>\$ 1.63</u>

<sup>(2)</sup>A blended statutory tax rate of 25% was used to calculate the tax effects of the adjustments.